Astria Therapeutics, Inc. - ATXS STOCK NEWS

Astria Therapeutics, Inc. (NASDAQ: ATXS) announced its upcoming presentations on STAR-0215, a monoclonal antibody for hereditary angioedema, at the American Academy of Allergy, Asthma, and Immunology Annual Meeting in San Antonio, Texas on February 26, 2023. Presentations by Dr. Chris Morabito and Dr. Nikolaos Biris will unveil critical Phase 1a trial data supporting STAR-0215's efficacy and innovative enzyme inhibition mechanism. The company plans to explore six-month dosing based on preliminary outcomes, with further data anticipated in mid-2024 from ongoing trials. Astria remains committed to developing therapies for rare immunological diseases.

Astria Therapeutics (NASDAQ:ATXS) has initiated the ALPHA-STAR Phase 1b/2 clinical trial of STAR-0215, aimed at treating hereditary angioedema (HAE). The trial will assess safety, tolerability, and quality of life for patients with HAE types I and II, with initial proof-of-concept results expected in mid-2024. Following promising Phase 1a results, Astria is optimistic about STAR-0215's potential as a long-acting preventative therapy. Additionally, preliminary results for six-month dosing are anticipated in Q4 2023, showcasing the company's commitment to addressing unmet needs in rare allergic and immunological diseases.

Astria Therapeutics, Inc. (NASDAQ: ATXS) has granted stock options to purchase 1,800 shares of common stock on February 1, 2023. This is part of the 2022 Inducement Stock Incentive Plan, aimed at facilitating equity awards for new employees. The options have an exercise price of $13.36, equal to the closing stock price on the grant date, and will vest over four years. The first 25% will vest on the first anniversary of the employee's start date, with the remainder vesting monthly thereafter, contingent on continued employment. Astria is focused on therapies for rare allergic and immunological diseases, particularly with its lead program, STAR-0215.

Astria Therapeutics (NASDAQ: ATXS) has successfully closed its underwritten offering of 10,445,050 shares at $11.01 per share, raising approximately $115 million in gross proceeds. The offering included the full exercise of an underwriters' option for 1,362,397 additional shares. Jefferies and Evercore ISI served as joint book-running managers. The shares were offered under an effective shelf registration statement filed with the SEC. This funding supports the company's development of STAR-0215, aimed at treating hereditary angioedema and other rare diseases.

Astria Therapeutics (ATXS) announced a public offering of 9,082,653 shares at $11.01 per share, aiming to raise approximately $100 million before expenses. Underwriters also hold a 30-day option to purchase an additional 1,362,397 shares. The offering is set to close around December 19, 2022, pending customary closing conditions. Jefferies and Evercore ISI are the joint book-running managers. The offering is conducted under a previously effective shelf registration statement with the SEC.

Astria Therapeutics (NASDAQ:ATXS) announced successful preliminary results from the Phase 1a trial of STAR-0215, a potential long-acting treatment for hereditary angioedema (HAE). The drug demonstrated a favorable safety profile and sustained drug levels for up to three months, with an estimated half-life of 110 days. The company plans to initiate the ALPHA-STAR Phase 1b/2 trial in HAE patients in Q1 2023, aiming for less frequent dosing. Results from the trial indicate promising pharmacokinetics, enhancing the prospect of STAR-0215 as a viable treatment option.

Astria Therapeutics, Inc. (NASDAQ:ATXS) announced the grant of stock options for 1,000 shares of its common stock as part of its 2022 Inducement Stock Incentive Plan. This grant, made on December 1, 2022, is aimed at new employees and complies with Nasdaq Listing Rule 5635(c)(4). The options have an exercise price of $11.00, matching the stock's closing price on the grant date, and will vest over four years. Astria is focused on developing STAR-0215 for hereditary angioedema and aims to deliver therapies for rare allergic and immunological diseases.

Astria Therapeutics, Inc. (NASDAQ:ATXS) reported Q3 2022 financial results, highlighting a net loss of $12 million and a loss per share of $0.87. The company is on track to release preliminary results from its Phase 1a clinical trial of STAR-0215, targeting hereditary angioedema, by the end of 2022. STAR-0215 shows promise with potential quarterly dosing based on preclinical data. Cash position stood at $116.6 million, sufficient to fund operations until mid-2024. R&D expenses increased to $7.7 million, while total expenses for the quarter were $12.4 million, reflecting ongoing development efforts.

Astria Therapeutics (Nasdaq: ATXS) announced that CEO Jill C. Milne will present a corporate overview of the company and its lead program STAR-0215 at the Jefferies London Healthcare Conference on November 16 at 7:25 AM GMT. STAR-0215 is a monoclonal antibody being developed for the treatment of hereditary angioedema, targeting rare allergic and immunological diseases. Investors can access a live webcast of the presentation here, with an archived replay available for 30 days after the event.